2000 RESprotect founded as a Fraunhofer-Society
spin-off.
2001 Start of the development of RP101 as a cancer
therapeutic.
2002 Start of the development of next generation product
candidates.
2004 North-American rights of RP101 out-licensed to
Avantogen Ltd., Los Angeles, California.
2007 North-American rights of RP101 transferred to
SciClone
Pharmaceuticals, Inc, Foster City, California.
2008 Korean rights of RP101 out-licensed to Kwang
Dong Pharmaceuticals, Seoul.
2008 Worldwide, randomized phase II/III
study evaluating RP101 combined with gemcitabine chemotherapy in patients
with pancreatic cancer initiated by SciClone Pharmaceuticals, Inc..
2008 Hsp27 confirmed as the novel and
unique target of RP101.
2009 Phase II/III study evaluating RP101
combined with gemcitabine chemotherapy in patients with pancreatic cancer
initiated by Kwang Dong Pharmaceuticals, Inc. in South Korea.
2009 RESprotect seeks partner(s) to develop RP101 in Europe, South
America, Asia and to develop its next generation product candidates worldwide.
